Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis

By
Luz M Toribio
Carolina Guzman
Alessandra Vasquez
Herbert Saavedra
Isidro Gonzales
Javier A Bustos
Hector H García
for the Cysticercosis Working Group in Peru
January 20, 2026
0 min

Open Forum Infectious Diseases

Objective:

To evaluate the performance of a newly developed Multiantigen Print Immunoassay (MAPIA) for antibody identification in neurocysticercosis (NCC) compared to the gold standard LLGP-EITB assay.

Key Findings:

MAPIA demonstrated a sensitivity of 97.7% and specificity of 97.4%.
Sensitivity was 100% for subarachnoid NCC and parenchymal NCC with >5 cysts.
Observed agreement with LLGP-EITB was 98.33%.

Interpretation:

MAPIA is a promising alternative to LLGP-EITB, offering comparable diagnostic performance while being simpler and more accessible for use in low-resource settings.

Limitations:

The study was conducted with a limited sample size from a single location.
Further validation in diverse settings is needed to confirm generalizability.

Conclusion:

MAPIA provides a cost-effective and efficient tool for diagnosing neurocysticercosis, potentially improving access to diagnostic services in resource-limited areas.

Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis

Related Content

Is the generalizability of a developed artificial intelligence algorithm for COVID-19 on chest CT sufficient for clinical use? Results from the International Consortium for COVID-19 Imaging AI (ICOVAI)

And the Beat Goes On

Recommender-based bone tumour classification with radiographs—a link to the past